Compare Abeona Therapeutics Inc (ABEO) vs ProShares Bitcoin ETF (BITO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs ProShares Bitcoin ETF — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while ProShares Bitcoin ETF trades at $8.44. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, ProShares Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | BITO | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Crypto-linked |
52-Week High | $7.23 | $23.05 |
52-Week Low | $4.17 | $7.98 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BITO trades at $8.64, up 3.6% over 24 hours amid a mixed technical picture with a bullish overall signal but bearish moving averages. Recent dividend distributions of $0.01-$0.02 per share provide modest income, though financial ratios like P/E and P/S are unavailable. News sentiment reflects caution as the fund faces scrutiny over performance gaps versus Bitcoin and fee structures.
Outlook remains clouded by volatile crypto markets and investor skepticism; risks include fee drag and regulatory uncertainty. Analysts highlight distribution cuts and correlation shifts, suggesting limited near-term catalysts. Investors should weigh income against potential capital erosion in a challenging environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ProShares Bitcoin ETF
BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.
Read more on BITO →
